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ABSTRACT
Background: In most people with glucose intolerance or type 2 diabetes mellitus (DM), there is a multiple set of risk factors that commonly 
appear together forming what is now known as the ‘Metabolic Syndrome’ (MS). This ‘clustering’ of metabolic abnormalities that occur in 
the same individual appear to confer substantial additional cardiovascular risk. There has been no report on the MS among patients with 
type 2 DM in urban North-central Nigeria.
Objective: The objective of this study was to determine the prevalence of the MS among urban North-central Nigerians with type 2 DM and 
to describe the frequency of the syndrome’s components.
Methods: Six hundred and thirty four (634) patients with type 2 diabetes attending the out-patient clinic of the Diabetes Screening and Care 
Centre, Jos, Nigeria were screened for the MS. A brief history was obtained and their anthropometric indices and blood pressure were 
measured. Fasting venous plasma samples were analyzed for lipids. Early morning spot urine samples were obtained for estimation of 
®microalbuminuria using the Bayer DCA 2000  machine. The diagnosis of MS was made based on the new International Diabetes Federation 
(IDF) definition.
Results: Of the 634 patients enrolled with mean (standard deviation/SD) age 54.2(9.1) years, 56% were females. The prevalence of MS was 
63.6% (74.5% in males and 54.9% in females, p<0.05). The mean (SD) age of patients with MS was 54.7(9.5) years. About 80% of the 
patients were centrally obese, 63% had hypertension, 62% had high triglycerides and 70% with low HDL-Chol. Among patients with MS, 
79% had dyslipidaemia, 41% had BMI e”30, and 36% had microalbuminuria.
Conclusion: The prevalence of the MS in this group of upland Nigerian patients with type 2 diabetes is moderately high. This probably 
reflects the adoption of Western lifestyles and diets that require intervention. 
Keywords: Prevalence, Metabolic syndrome, Diabetes.
INTRODUCTION
Each year, 3.2 million people around the world die from 
complications associated with diabetes. In countries with a high 
diabetes incidence, such as in the Pacific and the Middle East, as 
many as one in four deaths in adults aged between 35 and 64 years 
is due to the disease (1). Type 2 diabetes mellitus (DM), which 
accounts for 90% of all diabetes, has become one of the major 
causes of premature illness and death, mainly through increased 
risk of cardiovascular diseases (CVDs) which is responsible for up 
to 80% of these deaths (2). In most people with glucose intolerance 
or type 2 DM, there is a multiple set of risk factors that commonly 
appear together, forming what is now known as the ‘Metabolic 
Syndrome’ (MS). This clustering of metabolic abnormalities that 
occur in the same individual appear to confer a substantial 
additional cardiovascular risk over and above the sum of the risk 
associated with each abnormality (3,4). MS is a cluster of the most 
dangerous heart attack risk factors: diabetes and raised fasting 
plasma glucose, abdominal obesity, high cholesterol and high 
blood pressure (6,7). The underlying cause of MS continues to 
challenge the experts but both insulin resistance and central 
obesity are considered significant factors (8,9). Obesity is 
associated with insulin resistance and the MS. Central or 
abdominal obesity contributes to hypertension, high serum 
cholesterol, low high density lipoprotein (HDL)-cholesterol, 
high triglycerides and hyperglycaemia and is independently 
associated with higher CVD risk (9-11).
 It is estimated that around 20-25% of the world’s adult 
population have the MS and they are twice as likely to have a 
heart attack or stroke compared with people without the 
syndrome (7,12).  The more the components of the metabolic 
syndrome that are evident, the higher is the cardiovascular 
metabolic rate (8). There is paucity of reports on the metabolic 
syndrome in developing countries including Nigeria. The 
prevalence rates of the metabolic syndrome among patients with 
type 2 diabetes in Iraq (13) and Saudi Arabia (14) are 86% and 
56% respectively. The MS was seen in 51% of South-Western 
Nigerians (15). There has been no report on the MS from Jos, 
North-central Nigeria.
The objective of this study was to determine the prevalence 
of the MS among urban North-central Nigerians with type 2 
diabetes and to describe the frequency of the syndrome’s 
components.
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PATIENTS AND METHODS
Six hundred and thirty four (634) patients with type 2 diabetes 
attending the out-patient clinic of the Diabetes Screening and Care 
Centre, Jos, between January 2006 and December 2008 were 
screened for the MS. Patients known to have had type 2 DM for at 
least 6 months, and aged 30-80 years (most of whom were middle 
and upper cadre civil servants and business men/women) were 
consecutively enrolled after informed consent was obtained. All 
study subjects were residents of Jos metropolis and environs. The 
WHO Consultation and Expert Committee on the diagnosis, 
classification of DM criteria (5) was used for the diagnosis and 
classification of type 2 DM. A brief clinical history was obtained 
and their anthropometric indices and blood pressures were 
measured. Fasting venous plasma samples were analyzed for 
lipids. Microalbuminuria was quantitatively estimated from early 
®morning spot urine samples using the Bayer DCA 2000  machine. 
Information obtained was recorded in a pretested questionnaire 
prepared for the purpose of the study. The diagnosis of the MS was 
made based on the new IDF definition (6,7), Central obesity (waist 
circumference, [WC] e”94cm in males and e”80cm in females) 
plus two of the four factors: raised triglycerides (e”1.7mmol/l), 
reduced HDL-Chol (<1.03mmol/l in males and < 1.29mmol/l in 
females), raised BP (systolic BPe”130mmHg, or diastolic BPe” 
85mmHg or treatment of previously diagnosed hypertension), 
raised FPG (e”5.6mmol/l or previously diagnosed type 2 diabetes). 
Statistics: Data analysis was carried out using EPI-INFO (2002) 
statistical programme. Means (±SD) were calculated for 
quantitative data, and proportions for categorical variables. The 
student’s -t test was used for comparisons; p-values<0.05 were 
considered significant.
Ethics: Ethical approval was obtained from the Research and 
Ethical Committee of the Jos University Teaching Hospital, 
Plateau State and consent was obtained from each patient before 
the commencement of the study. 
RESULTS
Of the 634 patients enrolled with mean (SD) age 54.2 (9.1) 
years, 355 (56%) were females and 279 (44%) were males. There 
was no significant difference in the mean (SD) ages of males, 54.5 
(9.5) years and females, 53.7 (10.1) years, p>0.05. The MS was 
seen in 403 patients, 63.6% (51.6% males, 48.4% females). The 
prevalence rates of MS in males and females were 74.5% and 
54.9% respectively, being significantly higher in males than in 
females (p<0.05). The mean (SD) age of patients with MS was 54.7 
(9.5) years. Figure 1 shows the prevalence rates of the components 
of MS determined. About 80% of the study population was 
centrally obese using WC, 63.1% with hypertension, 62% with 
high triglycerides and 70% with low HDL-Cholesterol. The 
prevalence of dyslipidaemia in the patients with MS was 78.9%, 
the rates were 59.1% and 43.1% in males and females respectively 
(p<0.05).  The mean (SD) BMI of patients with MS was 29.8(4.4) 
2 2kg/m . Only 41.4% of patients with the MS had BMI e”30 kg/m . 
Microalbuminuria was detected in 34.6% of patients with the MS. 
The anthropometric and biochemical characteristics of the Patients 
with MS are summarized in table 1.
Figure 1: Components of Metabolic Syndrome























Among Persons with Type 2 Diabetes Mellitus.
Table 1: Anthropometric and Biochemical Features of 
Patients with the Metabolic Syndrome.
2BMI (Kg/m )                                                   Freq. (%)
                                                                                
18.5 -24.9                                                       38 (9.4%)
25.0 – 29.9                                                      198 (49.1%)
e” 30                                                               167 (41.4%)
WC (cm)                                                        Mean (SD)
Males                                                            98.6 (3.8)
Females                                                        91.3 (10.1)
Microalbuminuria                                         Freq. (%)
(5-300mg/L)                                                 139(  34.6%)
Dyslipidaemia 
Males                                                           165 (59.1%)
Females                                                       153 (43.1%)
DISCUSSION
Changing lifestyles, characterized by increase caloric 
intake and reduction in physical activity coupled with 
westernization have lead to an increase in prevalence of 
diabetes in the developing countries including Nigeria (6).
The World Health Organization (WHO) criteria for the MS 
(15) are different from those of the IDF (6,7). The WHO 
definition uses the BMI and includes microalbuminuria, which 
is often difficult to measure in tropical countries. Although, 
microalbuminuria was determined in our study, we used the IDF 
definition for MS.  In this study, we found a high prevalence of 
the MS (63.6%) in North-Central Nigeria. In comparison, MS 
was seen in 51% of South-Western Nigerians with type 2 
diabetes, where the WHO criteria were used (15). In the south 
western Nigerian study, the ratio of females to males with MS 
was 6:4 which is a reverse of the observation in this study, the 
use of different diagnostic criteria for MS may account for the 
difference. However, North-central Nigerian women have been 
known to be more active than the men. In Iraqi  (NIH–ATP 
 Panel III criteria) (9) and Saudi (WHO criteria) (14)  patients 
with type 2 diabetes, the prevalence rates of MS were 86% and 
56% respectively and the commonest component in both 
countries was hypertension. In this study, the commonest 
component of MS was abdominal obesity.  The prevalence rates 
of the MS and its components are strongly dependent on the 
definition of the different components of the syndrome, which 
are still not accepted globally. A possible explanation of the high 
rates of MS in Nigerian patients is the adoption of Western 
lifestyle (increased caloric intake and reduction in physical 
activity).  
The prevalence of the MS in this group of upland Nigerian 
patients with type 2 diabetes is high. This high figure is of great 
concern and probably reflects the adoption of Western lifestyles 
and dietary changes that require intervention. Further study 
needs to be carried out in rural Plateau State to throw more light 
on the aetiopathogenesis of the MS in this group of Nigerians.
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